APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologic Medications for Psoriasis

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Biologic Medications for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchBiologic Medications for Psoriasis Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologic Medications for Psoriasis Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Biologic Medications for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologic Medications for Psoriasis Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologic Medications for Psoriasis Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Biologic Medications for Psoriasis market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Biologic Medications for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biologic Medications for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologic Medications for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Biologic Medications for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Biologic Medications for Psoriasis include AbbVie Biotechnology, Amgen, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen Biotech, Kyowa Kirin, LEO Pharma and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Biologic Medications for Psoriasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologic Medications for Psoriasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologic Medications for Psoriasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biologic Medications for Psoriasis market size, projected growth trends, production technologies, key applications, and end-use industries.

Biologic Medications for Psoriasis Segment by Company

AbbVie Biotechnology

Amgen

Boehringer Ingelheim Pharmaceuticals

Bristol-Myers Squibb

Eli Lilly

Janssen Biotech

Kyowa Kirin

LEO Pharma

Novartis

Ortho Dermatologics

Pfizer

Samsung Bioepis

Tiefenbacher Pharmaceuticals

UCB

Dalian Yawei Pharmaceutical

Hanwha Chemical

China Medical System

Qilu Pharmaceutical

Biologic Medications for Psoriasis Segment by Type

Interleukin Inhibitors

Tyrosine Kinase Inhibitors

Phosphodiesterase Inhibitors

TNF-α Inhibitors

Other

Biologic Medications for Psoriasis Segment by Application

Retail Pharmacies

Hospital and Clinic

Other

Biologic Medications for Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologic Medications for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologic Medications for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologic Medications for Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biologic Medications for Psoriasis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biologic Medications for Psoriasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Biologic Medications for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Biologic Medications for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Biologic Medications for Psoriasis Industry Trends Table 2. Biologic Medications for Psoriasis Industry Drivers Table 3. Biologic Medications for Psoriasis Industry Opportunities and Challenges Table 4. Biologic Medications for Psoriasis Industry Restraints Table 5. Global Biologic Medications for Psoriasis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Biologic Medications for Psoriasis Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Biologic Medications for Psoriasis Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Biologic Medications for Psoriasis Sales Market Share by Manufacturers Table 9. Global Biologic Medications for Psoriasis Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Biologic Medications for Psoriasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Biologic Medications for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Biologic Medications for Psoriasis Manufacturers, Product Type & Application Table 13. Global Biologic Medications for Psoriasis Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Biologic Medications for Psoriasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Interleukin Inhibitors Table 17. Major Manufacturers of Tyrosine Kinase Inhibitors Table 18. Major Manufacturers of Phosphodiesterase Inhibitors Table 19. Major Manufacturers of TNF-α Inhibitors Table 20. Major Manufacturers of Other Table 21. Global Biologic Medications for Psoriasis Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Biologic Medications for Psoriasis Sales by Type (2021-2026) & (K Units) Table 23. Global Biologic Medications for Psoriasis Sales by Type (2027-2032) & (K Units) Table 24. Global Biologic Medications for Psoriasis Sales Market Share by Type (2021-2026) Table 25. Global Biologic Medications for Psoriasis Sales Market Share by Type (2027-2032) Table 26. Global Biologic Medications for Psoriasis Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Biologic Medications for Psoriasis Revenue by Type (2021-2026) & (K Units) Table 28. Global Biologic Medications for Psoriasis Revenue by Type (2027-2032) & (K Units) Table 29. Global Biologic Medications for Psoriasis Revenue Market Share by Type (2021-2026) Table 30. Global Biologic Medications for Psoriasis Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Retail Pharmacies Table 32. Major Manufacturers of Hospital and Clinic Table 33. Major Manufacturers of Other Table 34. Global Biologic Medications for Psoriasis Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Biologic Medications for Psoriasis Sales by Application (2021-2026) & (K Units) Table 36. Global Biologic Medications for Psoriasis Sales by Application (2027-2032) & (K Units) Table 37. Global Biologic Medications for Psoriasis Sales Market Share by Application (2021-2026) Table 38. Global Biologic Medications for Psoriasis Sales Market Share by Application (2027-2032) Table 39. Global Biologic Medications for Psoriasis Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Biologic Medications for Psoriasis Revenue by Application (2021-2026) & (K Units) Table 41. Global Biologic Medications for Psoriasis Revenue by Application (2027-2032) & (K Units) Table 42. Global Biologic Medications for Psoriasis Revenue Market Share by Application (2021-2026) Table 43. Global Biologic Medications for Psoriasis Revenue Market Share by Application (2027-2032) Table 44. Global Biologic Medications for Psoriasis Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Biologic Medications for Psoriasis Sales by Region (2021-2026) & (K Units) Table 46. Global Biologic Medications for Psoriasis Sales Market Share by Region (2021-2026) Table 47. Global Biologic Medications for Psoriasis Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Biologic Medications for Psoriasis Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Biologic Medications for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 51. North America Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 52. Europe Biologic Medications for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 54. Europe Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Biologic Medications for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Biologic Medications for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Biologic Medications for Psoriasis Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Biologic Medications for Psoriasis Sales by Country (2027-2032) & (K Units) Table 61. Global Biologic Medications for Psoriasis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Biologic Medications for Psoriasis Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Biologic Medications for Psoriasis Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Biologic Medications for Psoriasis Revenue Market Share by Region (2021-2026) Table 65. Global Biologic Medications for Psoriasis Revenue Market Share by Region (2027-2032) Table 66. AbbVie Biotechnology Company Information Table 67. AbbVie Biotechnology Business Overview Table 68. AbbVie Biotechnology Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. AbbVie Biotechnology Biologic Medications for Psoriasis Product Portfolio Table 70. AbbVie Biotechnology Recent Development Table 71. Amgen Company Information Table 72. Amgen Business Overview Table 73. Amgen Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Amgen Biologic Medications for Psoriasis Product Portfolio Table 75. Amgen Recent Development Table 76. Boehringer Ingelheim Pharmaceuticals Company Information Table 77. Boehringer Ingelheim Pharmaceuticals Business Overview Table 78. Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio Table 80. Boehringer Ingelheim Pharmaceuticals Recent Development Table 81. Bristol-Myers Squibb Company Information Table 82. Bristol-Myers Squibb Business Overview Table 83. Bristol-Myers Squibb Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Bristol-Myers Squibb Biologic Medications for Psoriasis Product Portfolio Table 85. Bristol-Myers Squibb Recent Development Table 86. Eli Lilly Company Information Table 87. Eli Lilly Business Overview Table 88. Eli Lilly Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Eli Lilly Biologic Medications for Psoriasis Product Portfolio Table 90. Eli Lilly Recent Development Table 91. Janssen Biotech Company Information Table 92. Janssen Biotech Business Overview Table 93. Janssen Biotech Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Janssen Biotech Biologic Medications for Psoriasis Product Portfolio Table 95. Janssen Biotech Recent Development Table 96. Kyowa Kirin Company Information Table 97. Kyowa Kirin Business Overview Table 98. Kyowa Kirin Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Kyowa Kirin Biologic Medications for Psoriasis Product Portfolio Table 100. Kyowa Kirin Recent Development Table 101. LEO Pharma Company Information Table 102. LEO Pharma Business Overview Table 103. LEO Pharma Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. LEO Pharma Biologic Medications for Psoriasis Product Portfolio Table 105. LEO Pharma Recent Development Table 106. Novartis Company Information Table 107. Novartis Business Overview Table 108. Novartis Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Novartis Biologic Medications for Psoriasis Product Portfolio Table 110. Novartis Recent Development Table 111. Ortho Dermatologics Company Information Table 112. Ortho Dermatologics Business Overview Table 113. Ortho Dermatologics Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Ortho Dermatologics Biologic Medications for Psoriasis Product Portfolio Table 115. Ortho Dermatologics Recent Development Table 116. Pfizer Company Information Table 117. Pfizer Business Overview Table 118. Pfizer Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Pfizer Biologic Medications for Psoriasis Product Portfolio Table 120. Pfizer Recent Development Table 121. Samsung Bioepis Company Information Table 122. Samsung Bioepis Business Overview Table 123. Samsung Bioepis Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Samsung Bioepis Biologic Medications for Psoriasis Product Portfolio Table 125. Samsung Bioepis Recent Development Table 126. Tiefenbacher Pharmaceuticals Company Information Table 127. Tiefenbacher Pharmaceuticals Business Overview Table 128. Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio Table 130. Tiefenbacher Pharmaceuticals Recent Development Table 131. UCB Company Information Table 132. UCB Business Overview Table 133. UCB Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. UCB Biologic Medications for Psoriasis Product Portfolio Table 135. UCB Recent Development Table 136. Dalian Yawei Pharmaceutical Company Information Table 137. Dalian Yawei Pharmaceutical Business Overview Table 138. Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Product Portfolio Table 140. Dalian Yawei Pharmaceutical Recent Development Table 141. Hanwha Chemical Company Information Table 142. Hanwha Chemical Business Overview Table 143. Hanwha Chemical Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. Hanwha Chemical Biologic Medications for Psoriasis Product Portfolio Table 145. Hanwha Chemical Recent Development Table 146. China Medical System Company Information Table 147. China Medical System Business Overview Table 148. China Medical System Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. China Medical System Biologic Medications for Psoriasis Product Portfolio Table 150. China Medical System Recent Development Table 151. Qilu Pharmaceutical Company Information Table 152. Qilu Pharmaceutical Business Overview Table 153. Qilu Pharmaceutical Biologic Medications for Psoriasis Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Qilu Pharmaceutical Biologic Medications for Psoriasis Product Portfolio Table 155. Qilu Pharmaceutical Recent Development Table 156. Key Raw Materials Table 157. Raw Materials Key Suppliers Table 158. Biologic Medications for Psoriasis Distributors List Table 159. Biologic Medications for Psoriasis Customers List Table 160. Research Programs/Design for This Report Table 161. Authors List of This Report Table 162. Secondary Sources Table 163. Primary Sources List of Figures Figure 1. Biologic Medications for Psoriasis Product Image Figure 2. Global Biologic Medications for Psoriasis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biologic Medications for Psoriasis Market Size (2021-2032) & (US$ Million) Figure 4. Global Biologic Medications for Psoriasis Sales (2021-2032) & (K Units) Figure 5. Global Biologic Medications for Psoriasis Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Biologic Medications for Psoriasis Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Interleukin Inhibitors Image Figure 9. Tyrosine Kinase Inhibitors Image Figure 10. Phosphodiesterase Inhibitors Image Figure 11. TNF-α Inhibitors Image Figure 12. Other Image Figure 13. Global Biologic Medications for Psoriasis Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Biologic Medications for Psoriasis Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Biologic Medications for Psoriasis Sales Market Share by Type (2021-2032) Figure 16. Global Biologic Medications for Psoriasis Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Biologic Medications for Psoriasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Biologic Medications for Psoriasis Revenue Market Share by Type (2021-2032) Figure 19. Retail Pharmacies Image Figure 20. Hospital and Clinic Image Figure 21. Other Image Figure 22. Global Biologic Medications for Psoriasis Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Biologic Medications for Psoriasis Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Biologic Medications for Psoriasis Sales Market Share by Application (2021-2032) Figure 25. Global Biologic Medications for Psoriasis Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Biologic Medications for Psoriasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Biologic Medications for Psoriasis Revenue Market Share by Application (2021-2032) Figure 28. North America Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Biologic Medications for Psoriasis Sales Market Share by Country (2021-2032) Figure 30. U.S. Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Biologic Medications for Psoriasis Sales Market Share by Country (2021-2032) Figure 35. Germany Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Biologic Medications for Psoriasis Sales Market Share by Country (2021-2032) Figure 42. China Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Biologic Medications for Psoriasis Sales Market Share by Country (2021-2032) Figure 50. Brazil Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Biologic Medications for Psoriasis Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Biologic Medications for Psoriasis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Biologic Medications for Psoriasis Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 61. North America Biologic Medications for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 63. Europe Biologic Medications for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Biologic Medications for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Biologic Medications for Psoriasis Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Biologic Medications for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Biologic Medications for Psoriasis Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Biologic Medications for Psoriasis Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Interleukin Inhibitors
  • Tyrosine Kinase Inhibitors
  • Phosphodiesterase Inhibitors
  • TNF-α Inhibitors
  • Other
Applications
  • Retail Pharmacies
  • Hospital and Clinic
  • Other
Companies covered
  • AbbVie Biotechnology
  • Amgen
  • Boehringer Ingelheim Pharmaceuticals
  • Bristol-Myers Squibb
  • Eli Lilly
  • Janssen Biotech
  • Kyowa Kirin
  • LEO Pharma
  • Novartis
  • Ortho Dermatologics
  • Pfizer
  • Samsung Bioepis
  • Tiefenbacher Pharmaceuticals
  • UCB
  • Dalian Yawei Pharmaceutical
  • Hanwha Chemical
  • China Medical System
  • Qilu Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biologic Medications for Psoriasis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biologic Medications for Psoriasis Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Biologic Medications for Psoriasis Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Biologic Medications for Psoriasis Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Biologic Medications for Psoriasis Market Dynamics
  1. 2.1 Biologic Medications for Psoriasis Industry Trends
  2. 2.2 Biologic Medications for Psoriasis Industry Drivers
  3. 2.3 Biologic Medications for Psoriasis Industry Opportunities and Challenges
  4. 2.4 Biologic Medications for Psoriasis Industry Restraints
3 Biologic Medications for Psoriasis Market by Manufacturers
  1. 3.1 Global Biologic Medications for Psoriasis Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Biologic Medications for Psoriasis Sales by Manufacturers (2021-2026)
  3. 3.3 Global Biologic Medications for Psoriasis Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Biologic Medications for Psoriasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biologic Medications for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Biologic Medications for Psoriasis Manufacturers, Product Type & Application
  7. 3.7 Global Biologic Medications for Psoriasis Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biologic Medications for Psoriasis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biologic Medications for Psoriasis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biologic Medications for Psoriasis Tier 1, Tier 2, and Tier 3
4 Biologic Medications for Psoriasis Market by Type
  1. 4.1 Biologic Medications for Psoriasis Type Introduction
  2. 4.1.1 Interleukin Inhibitors
  3. 4.1.2 Tyrosine Kinase Inhibitors
  4. 4.1.3 Phosphodiesterase Inhibitors
  5. 4.1.4 TNF-α Inhibitors
  6. 4.1.5 Other
  7. 4.2 Global Biologic Medications for Psoriasis Sales by Type
  8. 4.2.1 Global Biologic Medications for Psoriasis Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Biologic Medications for Psoriasis Sales by Type (2021-2032)
  10. 4.2.3 Global Biologic Medications for Psoriasis Sales Market Share by Type (2021-2032)
  11. 4.3 Global Biologic Medications for Psoriasis Revenue by Type
  12. 4.3.1 Global Biologic Medications for Psoriasis Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Biologic Medications for Psoriasis Revenue by Type (2021-2032)
  14. 4.3.3 Global Biologic Medications for Psoriasis Revenue Market Share by Type (2021-2032)
5 Biologic Medications for Psoriasis Market by Application
  1. 5.1 Biologic Medications for Psoriasis Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Hospital and Clinic
  4. 5.1.3 Other
  5. 5.2 Global Biologic Medications for Psoriasis Sales by Application
  6. 5.2.1 Global Biologic Medications for Psoriasis Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biologic Medications for Psoriasis Sales by Application (2021-2032)
  8. 5.2.3 Global Biologic Medications for Psoriasis Sales Market Share by Application (2021-2032)
  9. 5.3 Global Biologic Medications for Psoriasis Revenue by Application
  10. 5.3.1 Global Biologic Medications for Psoriasis Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Biologic Medications for Psoriasis Revenue by Application (2021-2032)
  12. 5.3.3 Global Biologic Medications for Psoriasis Revenue Market Share by Application (2021-2032)
6 Global Biologic Medications for Psoriasis Sales by Region
  1. 6.1 Global Biologic Medications for Psoriasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biologic Medications for Psoriasis Sales by Region (2021-2032)
  3. 6.2.1 Global Biologic Medications for Psoriasis Sales by Region (2021-2026)
  4. 6.2.2 Global Biologic Medications for Psoriasis Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biologic Medications for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Biologic Medications for Psoriasis Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Biologic Medications for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Biologic Medications for Psoriasis Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Biologic Medications for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Biologic Medications for Psoriasis Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Biologic Medications for Psoriasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Biologic Medications for Psoriasis Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Biologic Medications for Psoriasis Revenue by Region
  1. 7.1 Global Biologic Medications for Psoriasis Revenue by Region
  2. 7.1.1 Global Biologic Medications for Psoriasis Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Biologic Medications for Psoriasis Revenue by Region (2021-2026)
  4. 7.1.3 Global Biologic Medications for Psoriasis Revenue by Region (2027-2032)
  5. 7.1.4 Global Biologic Medications for Psoriasis Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Biologic Medications for Psoriasis Revenue (2021-2032)
  8. 7.2.2 North America Biologic Medications for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Biologic Medications for Psoriasis Revenue (2021-2032)
  11. 7.3.2 Europe Biologic Medications for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Biologic Medications for Psoriasis Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Biologic Medications for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Biologic Medications for Psoriasis Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Biologic Medications for Psoriasis Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AbbVie Biotechnology
  2. 8.1.1 AbbVie Biotechnology Company Information
  3. 8.1.2 AbbVie Biotechnology Business Overview
  4. 8.1.3 AbbVie Biotechnology Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AbbVie Biotechnology Biologic Medications for Psoriasis Product Portfolio
  6. 8.1.5 AbbVie Biotechnology Recent Developments
  7. 8.2 Amgen
  8. 8.2.1 Amgen Company Information
  9. 8.2.2 Amgen Business Overview
  10. 8.2.3 Amgen Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Biologic Medications for Psoriasis Product Portfolio
  12. 8.2.5 Amgen Recent Developments
  13. 8.3 Boehringer Ingelheim Pharmaceuticals
  14. 8.3.1 Boehringer Ingelheim Pharmaceuticals Company Information
  15. 8.3.2 Boehringer Ingelheim Pharmaceuticals Business Overview
  16. 8.3.3 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Pharmaceuticals Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Biologic Medications for Psoriasis Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Biologic Medications for Psoriasis Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Janssen Biotech
  32. 8.6.1 Janssen Biotech Company Information
  33. 8.6.2 Janssen Biotech Business Overview
  34. 8.6.3 Janssen Biotech Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Janssen Biotech Biologic Medications for Psoriasis Product Portfolio
  36. 8.6.5 Janssen Biotech Recent Developments
  37. 8.7 Kyowa Kirin
  38. 8.7.1 Kyowa Kirin Company Information
  39. 8.7.2 Kyowa Kirin Business Overview
  40. 8.7.3 Kyowa Kirin Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Kyowa Kirin Biologic Medications for Psoriasis Product Portfolio
  42. 8.7.5 Kyowa Kirin Recent Developments
  43. 8.8 LEO Pharma
  44. 8.8.1 LEO Pharma Company Information
  45. 8.8.2 LEO Pharma Business Overview
  46. 8.8.3 LEO Pharma Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 LEO Pharma Biologic Medications for Psoriasis Product Portfolio
  48. 8.8.5 LEO Pharma Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Biologic Medications for Psoriasis Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Ortho Dermatologics
  56. 8.10.1 Ortho Dermatologics Company Information
  57. 8.10.2 Ortho Dermatologics Business Overview
  58. 8.10.3 Ortho Dermatologics Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ortho Dermatologics Biologic Medications for Psoriasis Product Portfolio
  60. 8.10.5 Ortho Dermatologics Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Biologic Medications for Psoriasis Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Samsung Bioepis
  68. 8.12.1 Samsung Bioepis Company Information
  69. 8.12.2 Samsung Bioepis Business Overview
  70. 8.12.3 Samsung Bioepis Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Samsung Bioepis Biologic Medications for Psoriasis Product Portfolio
  72. 8.12.5 Samsung Bioepis Recent Developments
  73. 8.13 Tiefenbacher Pharmaceuticals
  74. 8.13.1 Tiefenbacher Pharmaceuticals Company Information
  75. 8.13.2 Tiefenbacher Pharmaceuticals Business Overview
  76. 8.13.3 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Tiefenbacher Pharmaceuticals Biologic Medications for Psoriasis Product Portfolio
  78. 8.13.5 Tiefenbacher Pharmaceuticals Recent Developments
  79. 8.14 UCB
  80. 8.14.1 UCB Company Information
  81. 8.14.2 UCB Business Overview
  82. 8.14.3 UCB Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 UCB Biologic Medications for Psoriasis Product Portfolio
  84. 8.14.5 UCB Recent Developments
  85. 8.15 Dalian Yawei Pharmaceutical
  86. 8.15.1 Dalian Yawei Pharmaceutical Company Information
  87. 8.15.2 Dalian Yawei Pharmaceutical Business Overview
  88. 8.15.3 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Dalian Yawei Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
  90. 8.15.5 Dalian Yawei Pharmaceutical Recent Developments
  91. 8.16 Hanwha Chemical
  92. 8.16.1 Hanwha Chemical Company Information
  93. 8.16.2 Hanwha Chemical Business Overview
  94. 8.16.3 Hanwha Chemical Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Hanwha Chemical Biologic Medications for Psoriasis Product Portfolio
  96. 8.16.5 Hanwha Chemical Recent Developments
  97. 8.17 China Medical System
  98. 8.17.1 China Medical System Company Information
  99. 8.17.2 China Medical System Business Overview
  100. 8.17.3 China Medical System Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 China Medical System Biologic Medications for Psoriasis Product Portfolio
  102. 8.17.5 China Medical System Recent Developments
  103. 8.18 Qilu Pharmaceutical
  104. 8.18.1 Qilu Pharmaceutical Company Information
  105. 8.18.2 Qilu Pharmaceutical Business Overview
  106. 8.18.3 Qilu Pharmaceutical Biologic Medications for Psoriasis Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Qilu Pharmaceutical Biologic Medications for Psoriasis Product Portfolio
  108. 8.18.5 Qilu Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biologic Medications for Psoriasis Value Chain Analysis
  2. 9.1.1 Biologic Medications for Psoriasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biologic Medications for Psoriasis Production Mode & Process
  6. 9.2 Biologic Medications for Psoriasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biologic Medications for Psoriasis Distributors
  9. 9.2.3 Biologic Medications for Psoriasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst